Shares of Novavax, Inc. (NVAX) are rising more than 5% Wednesday morning after the company said its partner SK bioscience received expanded manufacturing and marketing approval from the Korean Ministry of Food and Drug Safety (KMFDS) for Nuvaxovid booster Covid-19 vaccine for adults.
Novavax' COVID-19 vaccine is authorized for use as an adult booster in more than 35 countries.
NVAX, currently at $13.17, has traded in the range of $8.75-$103.57 in the last 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.